Published in J Nucl Med on December 13, 2010
11C-acetate for Treatment Response After Radiotherapy for HCC | NCT02549755
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res (2011) 1.69
11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med (2013) 1.60
¹⁸F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging (2014) 1.42
Radiation treatment monitoring using multimodal functional imaging: PET/CT ((18)F-Fluoromisonidazole & (18)F-Fluorocholine) and DCE-US. J Transl Med (2015) 1.39
Quantitative (18)F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring. EJNMMI Res (2017) 1.37
Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging (2012) 1.34
Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol (2012) 1.22
Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. Am J Nucl Med Mol Imaging (2013) 1.21
Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging (2013) 1.21
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol (2014) 1.14
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med (2011) 1.07
Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging (2011) 1.06
Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer. Theranostics (2012) 0.99
Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine. Am J Nucl Med Mol Imaging (2015) 0.99
Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.98
[18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations. Mol Imaging (2012) 0.95
New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol (2012) 0.95
First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging (2013) 0.94
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol (2012) 0.93
Radiolabelled probes for imaging of atherosclerotic plaques. Am J Nucl Med Mol Imaging (2012) 0.93
Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. J Nucl Med (2015) 0.91
PET/CT in prostate cancer: non-choline radiopharmaceuticals. Q J Nucl Med Mol Imaging (2012) 0.90
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Mol Imaging Biol (2016) 0.87
The use of (18)F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer. ACS Cent Sci (2015) 0.86
Functional imaging for prostate cancer: therapeutic implications. Semin Nucl Med (2012) 0.85
The Medical Case for a Positron Emission Tomography and X-ray Computed Tomography Combined Service in Oman. Sultan Qaboos Univ Med J (2013) 0.83
Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev (2012) 0.83
Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. PLoS One (2012) 0.82
Contrast-enhanced ultrasound as support for prostate brachytherapy treatment planning. J Contemp Brachytherapy (2012) 0.81
System a amino acid transport-targeted brain and systemic tumor PET imaging agents 2-amino-3-[(18)F]fluoro-2-methylpropanoic acid and 3-[(18)F]fluoro-2-methyl-2-(methylamino)propanoic acid. Nucl Med Biol (2014) 0.81
Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. Mol Imaging Biol (2014) 0.81
Target volume definition in high-risk prostate cancer patients using sentinel node SPECT/CT and 18 F-choline PET/CT. Radiat Oncol (2012) 0.81
Imaging metabolic heterogeneity in cancer. Mol Cancer (2016) 0.80
(18)F Sodium Fluoride PET/CT in Patients with Prostate Cancer: Quantification of Normal Tissues, Benign Degenerative Lesions, and Malignant Lesions. World J Nucl Med (2016) 0.80
Influence of (11)C-choline PET/CT on radiotherapy planning in prostate cancer. Rep Pract Oncol Radiother (2014) 0.80
Transbilayer phospholipids molecular imaging. EJNMMI Res (2011) 0.80
PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer. J Nucl Med (2016) 0.79
Prognostic Utility of PET in Prostate Cancer. PET Clin (2015) 0.79
Vitamin D, intermediary metabolism and prostate cancer tumor progression. Front Physiol (2014) 0.79
A Review of Imaging Methods for Prostate Cancer Detection. Biomed Eng Comput Biol (2016) 0.79
Sensitivity of PET/MRI to detect recurrence of prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.79
The metabolic fate of acetate in cancer. Nat Rev Cancer (2016) 0.78
Molecular and functional imaging for detection of lymph node metastases in prostate cancer. Int J Mol Sci (2013) 0.78
Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls. Transl Oncol (2014) 0.78
(11)C-acetate PET/CT in pre-therapeutic lymph node staging in high-risk prostate cancer patients and its influence on disease management - a retrospective study. EJNMMI Res (2014) 0.78
Contemporary approaches for imaging skeletal metastasis. Bone Res (2015) 0.78
Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence. Clin Nucl Med (2014) 0.78
Therapy assessment of bone metastatic disease in the era of (223)radium. Eur J Nucl Med Mol Imaging (2017) 0.78
Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells. Bioorg Med Chem Lett (2012) 0.77
Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate Cancer. Front Med (Lausanne) (2015) 0.77
FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging (2015) 0.77
Optimising (18)F-Choline PET/CT Acquisition Protocol in Prostate Cancer Patients. N Am J Med Sci (2012) 0.77
Analysis of intraprostatic therapeutic effects in prostate cancer patients using [(11)C]-choline pet/ct after external-beam radiation therapy. Curr Oncol (2013) 0.76
Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy. Indian J Nucl Med (2013) 0.76
Phase IIa Clinical Trial of Trans-1-Amino-3-(18)F-Fluoro-Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer. Asia Ocean J Nucl Med Biol (2014) 0.76
Radiopharmaceuticals as probes to characterize tumour tissue. Eur J Nucl Med Mol Imaging (2015) 0.76
Can Choline PET Tackle the Challenge of Imaging Prostate Cancer? Theranostics (2012) 0.76
(68)Ga-DOTA and analogs: Current status and future perspectives. Rep Pract Oncol Radiother (2014) 0.75
Detection of prostate cancer by an FDG-PET cancer screening program: results from a Japanese nationwide survey. Asia Ocean J Nucl Med Biol (2014) 0.75
Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature. BMC Cancer (2014) 0.75
Fully automated synthesis of [(18) F]fluoro-dihydrotestosterone ([(18) F]FDHT) using the FlexLab module. J Labelled Comp Radiopharm (2016) 0.75
PET/CT is a cost-effective tool against cancer: synergy supersedes singularity. Eur J Nucl Med Mol Imaging (2016) 0.75
Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med (2016) 0.75
Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer. Abdom Radiol (2016) 0.75
Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. Eur J Nucl Med Mol Imaging (2016) 0.75
A Comparative Study of (68)Gallium-Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography and Magnetic Resonance Imaging for Lymph Node Staging in High Risk Prostate Cancer Patients: An Initial Experience. World J Nucl Med (2017) 0.75
Furosemide diminishes ¹⁸F-fluoroethylcholine uptake in prostate cancer in vivo. Eur J Nucl Med Mol Imaging (2014) 0.75
Saving costs in cancer patient management through molecular imaging. Eur J Nucl Med Mol Imaging (2017) 0.75
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol (2005) 4.37
Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis (2006) 2.48
The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging (2008) 2.48
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med (2003) 2.16
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res (2005) 1.97
[(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging (2008) 1.96
Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med (2009) 1.87
[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging (2007) 1.84
11C-acetate PET imaging of prostate cancer. J Nucl Med (2002) 1.72
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology (1996) 1.72
Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology (2001) 1.67
Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res (2001) 1.67
The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol (1999) 1.65
Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med (2008) 1.62
Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology (2007) 1.61
1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med (2008) 1.57
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology (2002) 1.57
Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med (2008) 1.56
Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging (2008) 1.54
2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res (2005) 1.53
Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci (2000) 1.51
18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology (2010) 1.50
Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol (2006) 1.49
Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol (2002) 1.48
The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.46
Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med (2005) 1.46
Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol (2001) 1.39
Diffuse FDG uptake in acute prostatitis. Clin Nucl Med (2008) 1.39
11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol (2006) 1.36
Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging (2006) 1.35
FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun (2001) 1.34
11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol (2003) 1.34
Registration methodology for histological sections and in vivo imaging of human prostate. Acad Radiol (2008) 1.30
18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med (2007) 1.25
Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. Nat Rev Urol (2009) 1.24
Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncol Rep (2008) 1.24
The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol (1999) 1.23
Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med (2008) 1.23
Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. Urology (2004) 1.20
Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol (2002) 1.19
Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int (2007) 1.18
Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol (2006) 1.18
Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging (2005) 1.17
Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging (2002) 1.15
Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin (2003) 1.14
Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology (2006) 1.14
Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int (2003) 1.13
Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging (2003) 1.12
Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol (2002) 1.11
Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging (2005) 1.10
In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging (2005) 1.09
Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging (2002) 1.08
Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med (2000) 1.07
Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol (2005) 1.07
Radiation dose estimates in humans for (11)C-acetate whole-body PET. J Nucl Med (2004) 1.04
Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res (2004) 1.03
The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol (2009) 1.02
[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med (2008) 1.01
Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin (2007) 0.98
Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol (2009) 0.97
The natural history of prostate cancer. Urol Clin North Am (2003) 0.94
Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int (2003) 0.94
Pathology of prostate cancer and focal therapy ('male lumpectomy'). Anticancer Res (2009) 0.93
PET-CT for treatment planning in prostate cancer. Q J Nucl Med Mol Imaging (2009) 0.90
Prostate cancer--biology of metastasis and its clinical implications. World J Urol (1996) 0.90
[(18)F]Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology. Eur J Nucl Med Mol Imaging (2009) 0.90
Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. Prostate (2003) 0.89
Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging (2004) 0.89
Prostate cancer staging using imaging. BJU Int (2000) 0.88
11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int (2007) 0.87
Choline autoradiography of human prostate cancer xenograft: effect of castration. Mol Imaging (2009) 0.83
PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med (1997) 0.83
Role of Imaging in Prostate Cancer. PET Clin (2009) 0.81
[11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging (2008) 0.80
Highly efficient automated synthesis of [(11)C]choline for multi dose utilization. Appl Radiat Isot (2004) 0.78
18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med (2009) 1.52
[F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol (2008) 0.99
Fusion positron emission tomography-computed tomography demonstration of epidural metastases. Clin Nucl Med (2004) 0.79